Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Commerce Bank

Commerce Bank cut its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,715 shares of the biopharmaceutical company’s stock after selling 65 shares during the quarter. Commerce Bank’s holdings in Regeneron Pharmaceuticals were worth $7,059,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of REGN. Strategy Asset Managers LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $576,000. PNC Financial Services Group Inc. lifted its position in Regeneron Pharmaceuticals by 0.8% during the third quarter. PNC Financial Services Group Inc. now owns 18,325 shares of the biopharmaceutical company’s stock worth $19,264,000 after buying an additional 153 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth about $3,532,000. Fifth Third Wealth Advisors LLC grew its holdings in Regeneron Pharmaceuticals by 27.0% in the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 504 shares of the biopharmaceutical company’s stock valued at $530,000 after buying an additional 107 shares during the period. Finally, Prospera Financial Services Inc acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at about $778,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $745.48 on Friday. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The firm has a market cap of $81.92 billion, a P/E ratio of 18.45, a PEG ratio of 2.81 and a beta of 0.15. The stock has a fifty day moving average price of $953.38 and a two-hundred day moving average price of $1,028.16. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on REGN shares. Leerink Partners reissued a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Truist Financial cut their target price on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI dropped their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Finally, Oppenheimer dropped their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $1,099.55.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 7.48% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.